Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.
Haoran ZhangDongming ZhangJia LiuYuequan ShiXiaoyan LiuMin-Jiang ChenWei ZhongJing ZhaoYan XuMengzhao WangPublished in: Thoracic cancer (2023)
Deleterious mutations of these six genes were common in resected NSCLC and could serve as prognostic biomarkers.